Friday, July 07, 2017 1:51:42 AM
Here are my reasons
OXS-1550 Phase two data will be available in June of '18
By the end of this year Oxis will have at least two additional drugs in the clinic (Not including the drugs acquired in their recent acquisition.)
OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)
OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.
OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year
Here's what I think will happen over the next few months,
Oxis will uplist to the nasdaq and will change the company name. In order to do this they will do
a reverse split, then fund operations through selling shares at a price of $10.00 per share.
However, unfortunately for us, I believe they won't announce that Mace Rothenberg is the CMO
and instead save that for after the reverse split when they uplist.
Initiate the two clinical trials. The one trial OXS-3550 is a partnership with Altor Bioscience
which is owned by Dr. Patrick Soon Shiong.
Towards the end of the year and more probably next year, Pfizer will license the TRiKE platform
from Oxis
Final thoughts
Why do I think a top oncologist like Mace Rotherberg is even bothering with a small biotech
company like Oxis? Because he sees the potential the TRiKE platform and for the CNS piepline.
This isn't the first time Mace has done this. According to the Wall Street Journal, in November of
2011 Dr. Rothenberg. Flew out to California to look at promising clinical data for the compound
PD-0332991. However Pfizer wasn't willing to fund the continuing clinical trials and so he raised
money from outside investors. PD-0332991 went on to become ibrance and was initially licensed
to Pfizer and then Pfizer later on acquired the company in its entirety. But this isn't it, prior to
this, Pfizer had licensed an alzheimers drug named Dimebon from this company for 225 million.
This explains why Oxis acquired Georgetown Translational Pharmaceuticals. So whats the name
of this company. Medivation, a company Pfizer acquired for 14 billion or $81.50 a share.
According to a press release from 05/05/2017 "Both our TriSpecific Killer Engager (TriKE) and
Bispecific Killer Engager (BiKE) platforms are applicable to solid tumors (80% of the
marketplace) and liquid tumors (20% of the market). In addition to our planned clinical
development program, our strategy will include potentially out-licensing the technology to
Pharma and other biotech companies for specific applications," said Oxis Chairman & Chief
Executive Officer Anthony Cataldo.
http://www.nasdaq.com/press-release/oxis-international-expands-its-stateoftheart-trike-
technology-portfolio-20170503-00696
And there's also this from Mase Rothernberg. Oxis' incoming CMO said: "The drugs in the Oxis
pipeline are at the forefront of targeted immunotherapeutics and represent the wave of the future.
The non-clinical and clinical data is impressive and validates this approach to cancer therapy.
Once approved, these agents will herald a major breakthrough in the field of immunotherapy and
offer patients hope against some of the most difficult diseases to treat."
Keep in mind this is the
guy who said "I think we have something special" his words not mine in regards to PD-0332991
according to the wall street journal. PD-0332991 went on to later become IBRANCE.
Recent GTBP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/17/2024 08:26:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:25:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:31:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/23/2024 10:04:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 10:02:41 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:00:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM